AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01633827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
Study NCT01999309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
Study NCT01999309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
Study NCT02354378 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Study NCT02354378 — intervention group
Intervention type: OTHER
Intervention: Memory Test
Study NCT02266836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove
Description: During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
Study NCT00957983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGC20-1531
Description: oral administration followed by Prostaglandin E2 infusion
Study NCT01454154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Administered as specified in the Treatment Arm.
Study NCT00957983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BGC20-1531
Description: oral administration followed by Prostaglandin E2 infusion
Study NCT01725945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension dietary pattern
Description: The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
Study NCT02159105 — intervention group
Intervention type: DEVICE
Intervention: FAST scan and non-invasive hemoglobin measurement
Description: A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours).
Study NCT03150498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTD-001
Description: BTD-001 in fed vs fasted state
Study NCT04485988 — intervention group
Intervention type: DRUG
Intervention: Beta blocker
Description: Duration of medication
Study NCT00720798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For participants weighing > 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
Study NCT00720798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drugs
Description: Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
Study NCT00720798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs
Description: Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
Study NCT00720798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Description: Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
Study NCT01537484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage Therapy
Description: Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
Study NCT01537484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
Study NCT01537484 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Massage Therapy
Description: Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
Study NCT01803152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells Vaccine
Description: Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
Study NCT01803152 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cells Vaccine
Description: Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
Study NCT01803152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lysate of Tumor
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
Study NCT01803152 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lysate of Tumor
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
Study NCT01803152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
Study NCT01803152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
Study NCT01803152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
Study NCT01803152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
Study NCT01803152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukapheresis
Description: Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
Study NCT01809613 — intervention group
Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
Study NCT00757913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 enriched nutrition
Study NCT01454154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the Treatment Arm.
Study NCT03160612 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transfer Training
Description: Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
Study NCT04282148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABT NG DES 48 EECSS
Description: Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
Study NCT01224184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's CoOp
Description: Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
Study NCT01224184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staying Healthy and Eating Well
Description: Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
Study NCT04438083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX130
Description: CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Study NCT03551275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132
Description: Dose Escalation Study
Study NCT02524041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
Study NCT02524041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood specimen
Description: blood specimen
Study NCT04113954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 0.375% mepivacaine in nerve block
Study NCT04113954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Injection
Description: Injection of 1.5% mepivacaine in nerve block
Study NCT02605226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation therapy
Description: Cryoablation therapy
Study NCT02605226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: External beam radiation therapy
Study NCT02605226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: bicalutamide
Study NCT02605226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing-hormone releasing-hormone (LHRH) agonist
Description: luteinizing-hormone releasing-hormone (LHRH) agonist
Study NCT05598242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic membrane extract eye drops (AMEED)
Description: Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
Study NCT05598242 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane extract eye drops (AMEED)
Description: Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
Study NCT00597948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Curriculum
Description: Three consecutive days of six hours of training comprised of instruction and participant interaction.
Study NCT00943306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 5-60 mg po every day
Study NCT00973661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic tool set for counseling overweight patients
Description: Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients.
Study NCT03455322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine versus midodrine & octreotide
Description: either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
Study NCT01970605 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical reconstruction
Description: In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible.
Study NCT04309084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study NCT01957501 — intervention group
Intervention type: OTHER
Intervention: MDDScoreTM
Description: The child will receive a single blood draw (about 10 mL).
Study NCT02323087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLEXICULT™ SSI-Urinary Kit
Description: Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
Study NCT02323087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ID FlexicultTM
Description: Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
Study NCT03034018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: 10-20 mg taken at bedtime for four weeks
Study NCT03034018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken at bedtime for four weeks
Study NCT01194284 — intervention group
Intervention type: DRUG
Intervention: Mifamurtide
Description: Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
Study NCT03293329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm manual therapy techniques
Description: 3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
Study NCT03293329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm mobilization through active hipopressive gymnastic exercise
Description: Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
Study NCT03293329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic compression techniques in shoulder myofascial trigger points
Description: Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
Study NCT01939483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01939483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02608697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054
Study NCT02608697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02387957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista®
Study NCT02387957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT02387957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02387957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Study NCT02669836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression
Description: Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
Study NCT02669836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Augmentation
Description: The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
Study NCT02552238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Study NCT02542644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrahigh resolution Spectral Domain OCT
Description: The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
Study NCT03472222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arsha Vidya program
Description: Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
Study NCT00666432 — intervention group
Intervention type: OTHER
Intervention: This is an observational study model that is family based
Description: This is an observational study model that is family based
Study NCT02036645 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MEDI1814 for IV injection
Description: Monoclonal antibody for IV Injection
Study NCT02036645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1814 for IV injection
Description: Monoclonal antibody for IV Injection
Study NCT02036645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1814 for Subcutaneous Injection
Description: Monoclonal antibody for subcutaneous injection
Study NCT02036645 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Placebo for IV injection
Study NCT02036645 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Subcutaneous Injection
Description: Subcutaneous Placebo Injection
Study NCT04341961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: Drinking 8 oz of pomegranate juice daily for 2 weeks.